ArticleJournal of tropical pediatrics2026
Crimean-Congo Hemorrhagic Fever in Children: Secondary Hemophagocytic Lymphohistiocytosis and Time-course of Biomarkers in a Single-Center Cohort (2019-25).
Article in Journal of tropical pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral infection that may present mildly in children but can progress to severe clinical states due to secondary hemophagocytic lymphohistiocytosis (HLH). We retrospectively analyzed the clinical, laboratory, and treatment data of children aged 0-18 years with polymerase chain reaction (PCR)-confirmed CCHF who were hospitalized at Hacettepe University, a large referral center for CCHF, between January 2019 and July 2025. Serial laboratory values (Days 0, 3, 7, and 10) and therapeutic interventions were evaluated. Twenty-two children (median age 13 years, 72% male) were included. The most frequent symptoms were fever (100%), bradycardia (59%), and conjunctival hyperemia (41%). HLH was diagnosed in 18 patients (82%). Ribavirin (91%), intravenous immunoglobulin (IVIG) (86%), and corticosteroids (68%) were administered. Platelet counts began to recover by Day 7, whereas ferritin declined gradually and normalized later. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels showed a progressive decrease. No patient required intensive care, and none died. Secondary HLH was highly prevalent among pediatric CCHF cases, yet outcomes were favorable with early antiviral and immunomodulatory therapy. Platelet recovery and delayed ferritin normalization may serve as practical biomarkers of disease resolution. Prospective multicenter studies with cytokine and viral-load profiling are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.